← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #341 OF 1,000 MOST-CITED

Establishment of calibration procedures

FDA cited this observation 61 times across 60 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs61
BY FISCAL YEAR
FY20263
FY20254
FY20249
FY20236
FY20223
FY20212
FY20205
FY201910
FY201815
FY20174

How FDA worded it — real examples

Procedures describing the calibration of instruments, apparatus, gauges and recording devices are not written or followed.

Micron Inc · Wilmington, Delaware · Drugs · 2025-12-19

Procedures describing the calibration of instruments, apparatus, gauges and recording devices are not written or followed.

KaryoLogic Inc · Durham, North Carolina · Drugs · 2025-12-19

Procedures describing the calibration of instruments, apparatus, gauges and recording devices are not written or followed.

EO Products, LLC · San Rafael, California · Drugs · 2025-10-23

Procedures describing the calibration of instruments, apparatus, gauges and recording devices are not written or followed.

Pharbest Pharmaceuticals, Inc. · Farmingdale, New York · Drugs · 2025-09-15

Procedures describing the calibration of instruments, apparatus, gauges and recording devices are not written or followed and deficiently written or followed.

Kappa Laboratories, Inc. · Miami, Florida · Drugs · 2025-06-04

Procedures describing the calibration of instruments, apparatus, gauges and recording devices are not written or followed.

AVASOL LLC · Santa Barbara, California · Drugs · 2025-02-12

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemPharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →